📊 MNKD Key Takeaways
Is MNKD a Good Investment? Thesis Analysis
MannKind demonstrates revenue growth of 22.2% YoY and positive operating cash flow, indicating operational progress in a pharmaceutical environment. However, negative stockholders' equity of -51.0M, high debt burden of 354.6M, and deteriorating diluted EPS (-80% YoY) present substantial balance sheet concerns that offset near-term operational improvements.
Why Buy MNKD? Key Strengths
- Strong revenue growth of 22.2% YoY signals market demand and commercial execution
- Positive operating cash flow of 18.3M and free cash flow of 13.7M demonstrate ability to generate cash from operations
- Adequate liquidity with current ratio of 1.70x and cash position of 74.9M provides short-term financial flexibility
- Operating margin of 11.1% shows reasonable cost control at the operational level
MNKD Investment Risks to Consider
- Negative stockholders' equity of -51.0M indicates the company is technically insolvent on a balance sheet basis
- High long-term debt of 354.6M relative to operating cash flow creates refinancing and debt service risks
- Net margin of only 1.7% despite revenue growth shows minimal bottom-line profitability after interest and debt obligations
- Diluted EPS collapsed 80% YoY, signaling significant share dilution and deteriorating per-share economics
- Interest coverage of 4.5x provides limited cushion if operational performance declines
Key Metrics to Watch
- Trajectory of net income and diluted EPS to assess if profitability gains are sustainable
- Debt reduction progress and debt-to-operating cash flow ratio as indicator of financial stability
- Path to positive stockholders' equity through retained earnings accumulation
- Operating cash flow sustainability and conversion efficiency from revenue to cash
MNKD Financial Metrics
💡 AI Analyst Insight
The relatively thin 3.9% FCF margin may limit capital allocation flexibility.
MNKD Profitability Ratios
MNKD vs Healthcare Sector
How MANNKIND CORP compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MNKD Overvalued or Undervalued?
Based on fundamental analysis, MANNKIND CORP has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MNKD Balance Sheet & Liquidity
MNKD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MANNKIND CORP's revenue has grown significantly by 363% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.04 indicates the company is currently unprofitable.
MNKD Growth Metrics (YoY)
MNKD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $70.1M | $668.0K | $0.03 |
| Q2 2025 | $72.4M | $668.0K | $0.00 |
| Q1 2025 | $66.3M | $10.6M | $0.04 |
| Q3 2024 | $51.3M | $1.7M | $0.01 |
| Q2 2024 | $48.6M | -$2.0M | $-0.01 |
| Q1 2024 | $40.6M | -$9.8M | $-0.04 |
| Q3 2023 | $32.8M | $1.7M | $0.01 |
| Q2 2023 | $18.9M | -$5.3M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MNKD Capital Allocation
MNKD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MANNKIND CORP (CIK: 0000899460)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MNKD
What is the AI rating for MNKD?
MANNKIND CORP (MNKD) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MNKD's key strengths?
Claude: Strong revenue growth of 22.2% YoY signals market demand and commercial execution. Positive operating cash flow of 18.3M and free cash flow of 13.7M demonstrate ability to generate cash from operations.
What are the risks of investing in MNKD?
Claude: Negative stockholders' equity of -51.0M indicates the company is technically insolvent on a balance sheet basis. High long-term debt of 354.6M relative to operating cash flow creates refinancing and debt service risks.
What is MNKD's revenue and growth?
MANNKIND CORP reported revenue of $349.0M.
Does MNKD pay dividends?
MANNKIND CORP does not currently pay dividends.
Where can I find MNKD SEC filings?
Official SEC filings for MANNKIND CORP (CIK: 0000899460) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MNKD's EPS?
MANNKIND CORP has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MNKD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MANNKIND CORP has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MNKD stock overvalued or undervalued?
Valuation metrics for MNKD: ROE of N/A (sector avg: 15%), net margin of 1.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MNKD stock in 2026?
Our dual AI analysis gives MANNKIND CORP a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MNKD's free cash flow?
MANNKIND CORP's operating cash flow is $18.3M, with capital expenditures of $4.6M. FCF margin is 3.9%.
How does MNKD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.70 (avg: 2).